Elysium Health Launches Physician-Led Longevity Program — Moving From Supplements to Clinical Care
BiohackingElysium Health — best known for Basis, its NAD+ metabolism supplement — is launching The Elysium Longevity Institute (TELI), a physician-led program that bundles personalized supplements, prescriptions, peptides, and continuous clinical support under medical oversight. Initial enrollment is capped at 10,000 participants, with launch in Q3 2026.
What TELI Actually Covers
The program addresses four health domains under physician oversight: healthy aging, metabolic health and performance, detox and inflammation, and peptide-based interventions including vitamin injections. The clinical leadership is notable: Omar Baker, MD, formerly EVP and deputy chief medical officer at UnitedHealth Group, serves as Chief Medical Officer — a hire that signals integration with mainstream clinical standards rather than the supplement-adjacent positioning of most longevity programs.
Leonard Guarente, PhD, MIT’s Novartis Professor and one of the foundational researchers in sirtuin biology and NAD+ metabolism, co-founded the company and provides the scientific foundation that distinguishes TELI from less rigorously grounded programs. The stated philosophy: “from promise to proof” — longitudinal data tracking and clinical-grade oversight rather than narrative-based health claims.
The Market Signal
Elysium’s expansion from consumer supplements to physician-led care reflects a structural shift in the longevity space. Consumer supplementation — even well-formulated NAD+ precursors — faces a ceiling: without individualized dosing, biomarker tracking, and clinical context, the intervention is generic. The programs generating the most interesting data in longevity medicine (Peter Attia’s practice, Function Health, Hone Health, and similar) share a common architecture: continuous biomarker monitoring plus clinical interpretation plus protocol adjustment. TELI is entering that category.
The 10,000 participant cap suggests a deliberate Phase 1: build the longitudinal dataset, demonstrate outcomes, then scale. For practitioners and informed consumers evaluating longevity protocols, the TELI launch is worth tracking as a data point on what physician-supervised NAD+ and peptide protocols produce at population scale.
The So What
Consult a qualified healthcare provider before starting any longevity protocol, including those offered through physician-led programs. TELI represents a meaningful step toward evidence-based longevity medicine — the combination of clinical oversight, longitudinal tracking, and academic scientific foundation addresses the primary criticisms of supplement-only approaches. Whether the Q3 2026 launch delivers on the “from promise to proof” positioning will depend on the rigor of its outcome measurement. The enrollment cap and decade-long development timeline suggest Elysium is serious about generating publishable data, not just expanding its customer base.
Source: Longevity Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →